Humacyte(HUMA) - 2024 Q1 - Quarterly Results

Exhibit 99.1 -BLA Granted Priority Review for Vascular Trauma Indication; PDUFA date set for August 10, 2024- -Raised approximately $43 million in net proceeds from public offering of common stock- -Conference call and live webcast at 8:00 a.m. ET today- First Quarter 2024 and Recent Corporate Highlights Humacyte First Quarter 2024 Financial Results and Business Update HAV in Vascular Trauma -Biologics License Application (BLA) for HAV™ Accepted by FDA- 1 DURHAM, N.C., May 10, 2024 – Humacyte, Inc. (Nasdaq: ...